Carcinoma  >>  darleukin (L19IL2)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
darleukin (L19IL2) / Philogen
NCT01058538 / 2005-002716-16: A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours

Completed
1/2
33
Europe
L19IL2
Philogen S.p.A., Syneos Health
Advanced Solid Tumours
04/08
11/09

Download Options